Objectives. This study attempted to determine the long-term outcome of verapamil-sensitive sustained left ventricular tachycardia in patients without apparent structural heart disease.
Background. Several types of idiopathic ventricular tachycardia have been reported, and their clinical, electrophysiologic and electropharmacologic characteristics are different. It is possible that the prognosis of each type of ventricular tachycardia might also be different.
Methods. We studied mortality and morbidity in 37 consecutive patients (27 male, 10 female; mean [-+SD] age 33 -+ 14 years) with verapamil-sensitive sustained left ventricular tachycardia who had no apparent structural heart disease. Patients were followed up for 1 to 13 years (mean 5.8). Verapamil repeatedly terminated ventricular tachycardia in all patients. Ventricular tachycardia originated from the inferior and inferoseptal regions of the left ventricle in 33 patients and the superior and superioseptal regions in 4. Severity of ventricular tachycardia was classified according to the extent to which symptoms limited daily activities. Ventricular tachycardia was mild (minimal limitation) in 14 patients, moderate (some limitation) in 17 and severe (severe limitation) in 6.
Results. Fourteen patients with mild ventricular tachycardia were followed up without any drug therapy, and the ventricular tachycardia remained mild in all patients. Antiarrhythmic therapy was initiated empirically in the 23 patients with moderate and severe ventricular tachycardia (verapamil in 20, propranolol in 2, digoxin in 1). Moderate ventricnlar tachycardia became mild ventricular tachycardia after drug therapy in all patients, but the six patients with severe ventricular tachycardia showed no improvement. The six patients with severe ventricular tachycardia had nonpharmacoiogic therapy (cryosurgery in one, catheter ablation in four, antitachycardia pacing device in one). During the follow-up period, all patients remained alive except for one who died suddenly after implantation of an antitachycardia pacing device.
Conclusions. 1) The long-term prognosis of verapamil-sensitive sustained left ventricular tachycardia in patients without apparent structural heart disease is good. 2) Verapamil is the drug of choice for alleviating symptoms, but nonpharmacologic therapy is necessary in some patients.
(J Am Coil Cardiol 1995; 25:54-8) Idiopathic ventricular tachycardia is usually defined as ventricular tachycardia that occurs in patients without apparent heart disease or any identifiable predisposing cause of arrhythmia. The prognosis of patients who have ventricular tachycardia without apparent structural heart disease is believed to be good (1,2), but occasional sudden cardiac deaths have been described (1, 3) . Several types of idiopathic ventricular tachycardia have been reported (4) (5) (6) (7) (8) (9) , and their clinical and electrophysiologic characteristics are quite different. Thus, it is possible that the prognosis might also vary according to the type of idiopathic ventricular tachycardia. During the past 15 years, we have identified a group of patients with idiopathic ventricular tachycardia originating from the left ventricle that is sensitive to From the Department of Cardiovascular Medicine, Okayama University Medical School, Okayama and *Division of Cardiology, National Cardiovascular Center, Osaka, Japan.
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Ad___dress for Correspondence: Dr. Tohru Ohe, Department of Cardiovascular Medicine, Okayama University Medical School, 2-5-1, Shikata-cho, Okayama 700 Japan. verapamil (6) , but the long-term prognosis of this particular group of patients has been unclear. Thus, the purpose of this study was to determine the long-term outcome of verapamilsensitive sustained left ventricular tachycardia in patients without apparent structural heart disease.
Methods
Patients. The study included 37 patients (27 male, 10 female; mean age 33 years, range 12 to 68) seen at the National Cardiovascular Center between January 1979 and April 1992 who met the following inclusion criteria: 1) electrocardiographically documented recurrent sustained monomorphic ventricular tachycardia originating from the left ventricle; 2) no apparent structural heart disease; and 3) repeated termination of ventricular tachycardia by verapamil (Fig. 1) .
Ventricular tachycardia was diagnosed using standard electrocardiographic (ECG) criteria and confirmed from His bundle electrograms. The origin of ventricular tachycardia was determined by identifying the earliest ventricular activation site during ventricular tachycardia or by pace mapping during sinus rhythm. The presence of sustained dia was confirmed by ECG monitoring, and spontaneous termination was not recognized in any of the patients. The absence of organic heart disease was diagnosed on the basis of 1) normal findings on cardiac examination; 2) normal findings on the rest ECG and chest X-ray film; 3) lack of any significant ST depression or ST elevation during or after a submaximal treadmill exercise test; and 4) normal findings on the echocardiogram and radionuclide angiogram. The absence of organic heart disease was further confirmed by normal findings on coronary angiography, left ventriculography and right ventriculography in 17 patients.
Severity of ventricular tachycardia was classified according to the extent to which symptoms limited daily activities: mild (minimal limitation), moderate (some limitation) and severe (severe limitation).
Antiarrhythmic therapy was initiated empirically in patients with moderate or severe ventricular tachycardia. Patients were followed up for 1 to 13 years (mean 5.8) from hospital discharge to time of death or the last day of the study. The response of ventricular tachycardia to drug therapy was evaluated during the follow-up period, and the efficacy of nonpharmacologic intervention was also studied.
Statistics. The survival curve was obtained using the Kaplan-Meier method. Table 1 shows the clinical profile and follow-up data of all study patients. The age at onset of ventricular tachycardia was 10 to 19 years in 14 patients, 20 to 29 years in 11, 30 to 39 in 3, 40 to 49 years in 6, 50 to 59 years in 1 and >60 years in 2.
Results
The QRS configuration during ventricular tachyeardia was right bundle branch block with left-axis deviation in 33 patients ( Fig. 2A) , and their ventricular tachycardia originated from the inferior and inferoseptal regions of the left ventricle. The QRS configuration during ventricular tachycardia was right bundle branch block with right-axis deviation in the other four patients (Fig. 2B) , and the origin of their ventricular tachycardia was the superior and superoseptal region of the left ventricle.
Fourteen patients were classified as having mild, 17 had moderate and the remaining 6 had severe ventricular tachycardia. The 14 patients with mild ventricular tachycardia were followed up without any drug therapy. In all 14 patients, ventricular tachycardia remained mild, or symptomatic ventricular tachycardia ceased during the follow-up period. Antiarrhythmic therapy was initiated empirically in the patients with moderate and severe ventricular tachycardia. Verapamil (160 to 320 mg/day) was given to 20 patients either alone or in combination with other drugs (procainamide [1.5 to 2.0 g/day] in 3, propranolol [40 to 120 mg/day] in 2 and digoxin [0.25 rag/day] in 1). Propranolol (40 to 120 rag/day) administration alone was initiated in two patients and digoxin alone in one. In both patients taking digoxin, the effectiveness of this drug was confirmed by an electrical stimulation test that showed that ventricular tachycardia became noninducible during digoxin therapy. Of the 23 patients in whom antiarrhythmic drugs were initiated, 6 became free of symptomatic ventricular tachycardia, and ventricular tachycardia became mild in another 11. However, all six patients with severe ventricular tachycardia continued to have ventricular tachycardia episodes that severely limited their daily activities despite various drug regimens.
Accordingly, patients with severe ventricular tachycardia had nonpharmacologic therapy. Cryoablation was performed in one patient (Patient 31) and catheter ablation in four patients (Patients 22, 25, 32 and 36); an antitachycardia device was implanted in one patient (Patient 8). Three patients with catheter ablation (Patients 25, 32 and 36) and one with cryoablation (Patient 31) became free of symptomatic ventricular tachycardia after these procedures. One patient with catheter ablation (Patient 22) had recurrent ventricular tachycardia that was controlled by verapamil therapy. The patient with the implanted antitachycardia device died suddenly at home on the day of discharge from hospital. Actuarial survival is shown in Figure 3 . All patients remained alive, except for the one with the antitachycardia device.
Discussion
Effect of oral verapamil. Oral verapamil alone or in combination with other drugs was effective in alleviating the symptoms of most of our patients with moderate ventricular tachycardia. However, the patients with severe ventricular tachycardia were not helped by verapamil administration, and all eventually required nonpharmacologic treatment. The discrepancy between the effectiveness of intravenous and oral verapamil in the patients with severe ventricular tachycardia was probably related to differences in the drug concentration achieved through each route. The two patients who responded to digoxin were worthy of note. They were initially misdiagnosed as having supraventricular tachycardia and were thus given digoxin, but this drug was actually able to prevent the initiation of ventricular tachycardia by ventricular stimulation in both patients.
Nonpharmacologic treatment. There has been increasing interest in the nonpharmacologic treatment of tachyarrhythmias, including antitachycardia pacing, implantable automatic cardioverter-defibrillators and ablative techniques, such as catheter ablation or map-guided cryosurgery. In patients with recurrent sustained ventricular tachycardia who do not respond to antiarrhythmic therapy, surgical intervention also offers a reasonable alternative because the introduction of intraoperative mapping to localize the site of origin of ventricular tachycardia has improved the results. In our series, one Long-terra prognosis. The present study confirmed previous findings (1,2) that idiopathic ventricular tachycardia has an excellent prognosis, suggesting that patients with verapamilsensitive sustained left ventricular tachycardia probably should be treated on a symptomatic basis. The patients with mild ventricular tachycardia remained mildly symptomatic without any therapy during follow-up. In contrast, the patients with severe ventricular tachycardia remained severely symptomatic despite verapamil therapy and required nonpharmacologic intervention. The patients with moderate ventricular tachycardia were likely to respond to verapamil, and such patients should be considered for oral verapamil therapy. However, radiofrequency ablation might become an alternative therapy for patients with moderate ventricular tachycardia because many patients prefer definite cure of their arrhythmia rather than long-term antiarrhythmic therapy.
